| Autor: |
Akhil Kapoor, MD, DM, Vanita Noronha, MD, DM, Vijay Patil, MD, DM, Nandini Menon, MD, DNB, Amit Joshi, MD, DM, Amit Kumar, MD, DM, Ajay Kumar Singh, MD, DM, Abhishek Mahajan, MD, Amit Janu, MD, Rajiv Kumar, MD, Trupti Pai, MD, Anuradha Chougule, MD, Omshree Shetty, MD, Kumar Prabhash, MD, DM, ECMO |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
JTO Clinical and Research Reports, Vol 4, Iss 1, Pp 100443- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2666-3643 |
| DOI: |
10.1016/j.jtocrr.2022.100443 |
| Popis: |
Introduction: ALK inhibitors are one of the success stories in precision medicine for treating patients with advanced ALK-positive NSCLC. Nevertheless, developing countries have substantial constraints in using ALK inhibitors, with limited data from India. Methods: An audit of a prospectively collected database of patients with advanced ALK-positive NSCLC treated from January 2013 to March 2018 was conducted. The SPSS version 20.0 was used for statistical analysis. Results: A total of 441 patients were available for analysis; 62.5% were males, median age was 50 (range: 19–75) years, and 78.3% had Eastern Cooperative Oncology Group performance status of 0 to 1. When all the lines of therapies were included in the analysis, ALK inhibitors could be used in 379 (85.9%) of the total ALK-positive patients and 292 patients (66.2%) received ALK inhibitors in the first line in any strategy. The major reason for not starting ALK inhibitors upfront was financial constraints in 69% of the patients. The median progression-free survival on first-line therapy for the entire cohort was 14.1 months (95% confidence interval [CI]: 12.2–15.9), with a significant difference between patients receiving ALK inhibitor in first line in any strategy versus not in first line (17.2 mo [95% CI: 14.5–19.9] versus 5.9 mo [95% CI: 4.2–7.6], p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
